Anti-GITR antibodies for cancer diagnostics

US11408889B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Xi-Tao Wang · Wellesley, US
• Olufemi A. Adelakun · Kendall Park, US
• Anne C. Lewin · Lawrenceville, US
• Alan J. Korman · Piedmont, US
• Mark J. Selby · San Francisco, US
• Changyu Wang · Union City, US
• Haichun Huang · Fremont, US
• Karla A. HENNING · Milpitas, US
• Nils Lonberg · Woodside, US
• Mohan Srinivasan · Cupertino, US
• Michelle Minhua HAN · Piedmont, US
• Guodong Chen · East Brunswick Township, US
• Richard Y. Huang · Princeton, US
• Indrani Chakraborty · Fremont, US
• Susan WONG · Fremont, US
• Huiming LI · Lexington, US

Key dates

• Filing date: May 8, 2020
• Grant date: Aug 9, 2022
• Expiry date: Sep 6, 2040

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/7028
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.